Genedrive Share Discussion Threads

[premium beeks] 31/7/2024 06:45

Experts also highlighted that, in the future, pharmacogenomic testing may be reactive when clopidogrel is needed, but pre‑emptive pharmacogenomic tests for other treatments could be done at the same time. This would require a panel of tests that would be more easily done in a laboratory. There was also relatively little evidence for Genedrive (see section 3.15). So, despite Genedrive having the highest net benefit of the 3 tests assessed in modelling, the committee concluded that laboratory-based testing was its preferred method.

[z1co] 31/7/2024 06:45

I have been trading PPP up to 10p without even posting

SOLD MY LAST TRADE YESTERDAY.

Waiting for the pullback before buying in again

[z1co] 31/7/2024 06:43

Pre market 4.50p V 4.60p

No will be selling these at 4.50p but plenty will doubt be buying @ sub 5p

[premium beeks] 31/7/2024 06:42

Z1co, those things are not zero cost. I think you'll find (rightly so) that those coffers will be getting filled very quickly from shareholders.

Anyway, enjoy your day, you should make a mint today!

Btw, don't assume people don't already have positions, i'm just not a ramping noisy nasty piece of work like you.

[purple11] 31/7/2024 06:42

you cant bear to say it can you!!

wannabee SPIV

[premium beeks] 31/7/2024 06:41

From the other thread

"Z1co We have done it"

LoL!

What did you "do" Hazl, exactly? Outside of buying in the 20s and working your way down whilst pushing it, until it nearly went bust at 1.5p.

Are you really that stupid to think you "did" anything?

Why do you think people are "Hoping they can get back in"? You do know anyone can buy on the market, there's no shortage of shares here.

[z1co] 31/7/2024 06:40

From rns:

With UKCA certification for the product already achieved, completion of the DEVOTE clinical phase, and today's final guidance from NICE recommending the Genedrive® CYP2C19 ID kit for use in point-of-care settings, the Company will now actively pursue commercialisation in the UK and Middle Eastern countries where device registration is enabled by UKCA certification, and is fully prepared to supply and meet the anticipated demand.

[premium beeks] 31/7/2024 06:40

You are way off Batiatus. You are just here because of a grudge. The rest are here as we actively buy and sell it.

This will rise today, without a doubt. But it's a line in the sand no question, there's a road ahead which will be bumpy for shareholders. It's irrelevant today though, the noisy baseless rampers will have the upper hand.

[z1co] 31/7/2024 06:39

READ IT AGAIN OLD MAN

The Company will now actively pursue commercialisation in the UK and Middle Eastern countries where device registration is enabled by UKCA certification, and is fully prepared to supply and meet the anticipated demand.

[z1co] 31/7/2024 06:38

Mr Beeksy from up north in LEEDS is trying to deramp so he can buy them slightly cheap

ON YER BIKE OLD MAN!

From rns:

With UKCA certification for the product already achieved, completion of the DEVOTE clinical phase, and today's final guidance from NICE recommending the Genedrive® CYP2C19 ID kit for use in point-of-care settings, the Company will now actively pursue commercialisation in the UK and Middle Eastern countries where device registration is enabled by UKCA certification, and is fully prepared to supply and meet the anticipated demand.

[batiatus] 31/7/2024 06:38

Initial spike and then drift back down

[batiatus] 31/7/2024 06:37

Exactly Beeks.

Won't be buying a bean here.

RNS is nothing we don't already know.

Still many uncertainties ahead.

Red day

[kubera369] 31/7/2024 06:36

GDR went from 12p - 30p in March 2022.4. Last year GDR soared from 8p to 32p on positive news.We could be looking at 20p a share soonish on the back of this news. £100 Million revenues annually for the CYP2C19-ID test is huge, especially when you focus on the following:1. 1 in 4 adults over the age of 25 will have a stroke in their lifetime.2. Over 12 million people worldwide will have their first stroke this year3. 6.5 million will die as a result of a stroke this year.This is a HOLD for GOLD moment!

[purple11] 31/7/2024 06:35

come on spit it out.....

2p

PMSL!!!!!

[z1co] 31/7/2024 06:33

Pre market open at around 4.5p

Hey CLOWN buy some at the open price will rise very strongly.

[diggit180] 31/7/2024 06:33

Great RNS there's no denying it

[hazl] 31/7/2024 06:32

The ones suggesting it will be sold into are hoping they can get in.


They were too compacent about this company.



I am delighted.

[premium beeks] 31/7/2024 06:30

A great detailed announcement telling people what is already known. It will spike of course, but that will be heavily sold in to as this is a sell on fact day.

The hard work starts now - lab changes to accomadate, ramping up manufacturing. Additionally the NICE announcement needs careful reading as GDR are quite selective in their RNS:

mplementing laboratory-based CYP2C19 genotype testing for everyone who has a stroke or TIA would result in a large population being tested, which may require testing capacity to be scaled up over time. When implementing testing, commissioners may wish to consider:

a phased rollout with testing initially offered to people with a higher risk of stroke recurrence who could benefit most from it, such as people who have had a non‑minor stroke

This could actually delay revenues for GDR.

Additionally Centralised laboratory testing would also provide more consistency across the NHS. So, laboratory tests should be used if possible, and the Genedrive CYP2C19 ID Kit should be used when laboratory-based testing is not available.. The guidance is to use the Lab rather than poc GDR products.

It's not the nirvana announcement that the rampers were hoping for, but its'a great step forward in stroke care and will likely give share price appreciation short term today. I doubt they have the funds however to take this forward without needing the hat out from inverstors again.

Have a good day all.

[hazl] 31/7/2024 06:28

'With UKCA certification for the product already achieved, completion of the DEVOTE clinical phase, and today's final guidance from NICE recommending the Genedrive® CYP2C19 ID kit for use in point-of-care settings, the Company will now actively pursue commercialisation in the UK and Middle Eastern countries where device registration is enabled by UKCA certification, and is fully prepared to supply and meet the anticipated demand.'


Look at that....'is fully prepared to supply and meet the anticipated demand'!

[purple11] 31/7/2024 06:26

you havent answered the question

what price did you sell PPP for?

lol

[hazl] 31/7/2024 06:26

Z1CO We have done it!

[z1co] 31/7/2024 06:26

Battibou

They have £5m cash that's more than enough for the 18 months

[z1co] 31/7/2024 06:24

purple you CLOWN you don't have a CLUE.
You sold these at only 1.70p

LOLOL

ON YER BIKE!

10P or more

[batiatus] 31/7/2024 06:24

No funding strategy.

Placing soon?